PT Kalbe Farma Tbk. completed the acquisition of a 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.
October 25, 2022
Share
PT Kalbe Farma Tbk. (IDX:KLBF) entered into agreement to acquire 80% stake in PT Aventis Pharma (Indonesia) from Hoechst GmbH and Sanofi-Aventis Participations S.A.S. on July 22, 2022. Transaction is expected to be effectively implemented in Q4 2022 subject to the fulfillment of certain conditions as part of the SPA. As of September 20, 2022, The transaction is expected to complete in October.
PT Kalbe Farma Tbk. (IDX:KLBF) completed the acquisition of a 80% stake in PT Aventis Pharma (Indonesia) from Hoechst GmbH and Sanofi-Aventis Participations S.A.S. on October 26, 2022.
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.